Publikation

Subjective cognitive complaints one year after ceasing adjuvant endocrine treatment for early-stage breast cancer

Wissenschaftlicher Artikel/Review - 24.04.2012

Bereiche
PubMed
DOI

Zitation
Ribi K, BIG 1-98 Collaborative Group, Bernhard J, Gelber R, Price K, Goldhirsch A, Coates A, Pagani O, Cardoso F, Thürlimann B, Harvey V, Thompson A, Phillips K, Aldridge J, International Breast Cancer Study Group. Subjective cognitive complaints one year after ceasing adjuvant endocrine treatment for early-stage breast cancer. Br J Cancer 2012; 106:1618-25.
Art
Wissenschaftlicher Artikel/Review (Englisch)
Zeitschrift
Br J Cancer 2012; 106
Veröffentlichungsdatum
24.04.2012
eISSN (Online)
1532-1827
Seiten
1618-25
Kurzbeschreibung/Zielsetzung

BACKGROUND
In the BIG 1-98 trial objective cognitive function improved in postmenopausal women 1 year after cessation of adjuvant endocrine therapy for breast cancer. This report evaluates changes in subjective cognitive function (SCF).

METHODS
One hundred postmenopausal women, randomised to receive 5 years of adjuvant tamoxifen, letrozole, or a sequence of the two, completed self-reported measures on SCF, psychological distress, fatigue, and quality of life during the fifth year of trial treatment (year 5) and 1 year after treatment completion (year 6). Changes between years 5 and 6 were evaluated using the Wilcoxon signed-rank test. Subjective cognitive function and its correlates were explored.

RESULTS
Subjective cognitive function and the other patient-reported outcomes did not change significantly after cessation of endocrine therapy with the exception of improvement for hot flushes (P=0.0005). No difference in changes was found between women taking tamoxifen or letrozole. Subjective cognitive function was the only psychosocial outcome with a substantial correlation between year 5 and 6 (Spearman's R=0.80). Correlations between SCF and the other patient-reported outcomes were generally low.

CONCLUSION
Improved objective cognitive function but not SCF occur following cessation of adjuvant endocrine therapy in the BIG 1-98 trial. The substantial correlation of SCF scores over time may represent a stable attribute.